Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Kiadis Pharma Granted U.S. Patent for its Blood Cancer Treatment ATIR™

Published: Monday, January 21, 2013
Last Updated: Monday, January 21, 2013
Bookmark and Share
ATIR™ is a cell-based product that enables stem cell transplantations from mismatched donors.

Kiadis Pharma B.V. announced that it has received a Notice of Allowance for its U.S. Patent Application No. 10/969,011 regarding the Company’s lead product ATIR™. ATIR™ is a cell-based product that enables stem cell transplantations from mismatched donors.

The U.S. patent covers the composition of matter of a rhodamine derivative used in manufacturing ATIR™, all key steps of the manufacturing process of ATIR™ and the therapeutic use of ATIR™ to prevent graft-versus-host disease associated with allogeneic stem cell transplantations. Kiadis Pharma has previously been granted similarly broad patent protection for ATIR™ in Europe.

Manfred Ruediger, PhD, Chief Executive Officer of Kiadis Pharma, commented: “We are delighted about the broad patent protection for ATIR™ in the world’s largest pharmaceutical market. This broad patent protection provides a strong basis for future commercialization of ATIR™ to the benefit of patients”.

Denis-Claude Roy, MD, Professor of Hematology at the Maisonneuve-Rosemont Hospital and the University of Montreal, and Inventor, added: “ATIR™ has the potential to change the current paradigm in allogeneic stem cell transplantation for patients with advanced blood cancers. We are excited that our invention of selectively removing patient reactive cells from a stem cell donation is being developed by Kiadis Pharma to prevent graft-versus-host disease and improve patient outcome”.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More Than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Kiadis Pharma Completes Five-year Follow-up of its Phase I/II Clinical Study with Blood Cancer Product ATIR™
67% survival demonstrated after 5 years and no transplant related mortalities.
Tuesday, September 17, 2013
Kiadis Pharma Receives Regulatory Approval from Health Canada
Company has received No Objection Letter for its new clinical study with ATIR™.
Thursday, February 28, 2013
Kiadis Pharma Raises EUR 10 Million in Financing Round
Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, has raised EUR 10 million in an equity financing round.
Tuesday, November 20, 2012
Kiadis Pharma Receives IND Approval From FDA to Start Pivotal Clinical Trial With ATIR(TM) in the United States
Biopharmaceutical Company Kiadis Pharma announced today that it has received approval for its Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) to start the pivotal clinical study for its product ATIR(TM) in the United States.
Friday, July 09, 2010
Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
Transporting Microscopic Cargo Between Human Cells
Scientists have developed a virus-inspired delivery system for material transport between cells.
Metabolite Promotes Cancer Cell Transformation
Researchers have identified a metabolite that promotes cancer cell transformation and colorectal cancer spread.
Improving Drug Production with Computer Model
A model has been developed that can be used to improve and accelerate the production of biotherapeutics, cancer drugs, and vaccines.
Zika’s Entry Points
Discovery shows Zika infection of neural progenitor cells occurs regardless of AXL production, which was thought to be the main vector for the virus.
New Form of Autism Found
An international team of researchers have identified a new form of syndromic autism.
Radiation-Free Imaging in the Brain
Scientists create sensors that use proteins to detect particular targets through induced blood flow changes.
Failings in Conveying Risks of Undercooked Meat
A study has found that restaurants do not communicate the risks of eating undercooked meats.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!